The aim of this research was to develop and validate a spectrofluorimetric method for determination of tranexamic acid in hydrogel patch formulations. Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid, trans-AMCHA) is an antifibrinolytic drug that recently gained attention as a skin-whitening agent due to its inhibitory effect on ultraviolet (UV)-induced pigmentation in vivo. Derivatization with naphthalene-2,3-dicarboxaldehyde (NDA) in the presence of cyanide ion (CN(-)) to produce a fluorescent 1-cyanobenz[f]isoindole (CBI) product (lambda(ex) = 420 nm, lambda(em) = 480 nm) is for the first time reported for the determination of tranexamic acid in hydrogel patch formulations. Other separation techniques were not used in the analysis of the CBI-fluorescent product as required in the previous studies. The developed method was proven to be precise and accurate with percent recoveries ranging between 98.0% and 101.8% at the concentration range of 8.4-84.0 microg/ml (R(2) > 0.999). The intra- and inter-day precisions as expressed by the relative standard deviations (RSD) were below 1.85%. Derivatization of tranexamic acid with NDA/CN(-) was completed within five minutes and was stable for at least 30 minutes. The method has been applied to the analysis of drug content and release profiles in tranexamic hydrogel patch formulations.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tranexamic acid
20
hydrogel patch
16
patch formulations
16
determination tranexamic
12
acid hydrogel
12
tranexamic
6
acid
6
spectrofluorimetric determination
4
hydrogel
4
patch
4

Similar Publications

Background: Uncertainty about optimal tranexamic acid (TXA) dosage has led to significant practice variation in hip arthroplasty. We aimed to identify the optimal i.v.

View Article and Find Full Text PDF

Tranexamic Acid and Heterotopic Ossification Formation Following Elbow Surgery: A Prospective Randomized Controlled Trial.

J Orthop Trauma

January 2025

The Hand and Upper Extremity Surgery Unit, Department of Orthopaedic Surgery, Yitzhak Shamir Medical Center affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tzrifin, Israel.

Objectives: This study investigates whether the intra-operative administration of intravenous tranexamic acid (TXA), known for its hemostatic and potential anti-inflammatory properties, affects the incidence of heterotopic ossification (HO) following surgery for elbow fracture-dislocations.

Methods: Design: Prospective, randomized clinical trial.

Setting: Hand and Upper Extremity Surgery Unit.

View Article and Find Full Text PDF

Factor XIa Inhibitor Reversal in Intracranial Hemorrhage: A Case Report.

Neurohospitalist

January 2025

Department of Neurology, Division of Neurocritical Care, University of North Carolina, Chapel Hill, NC, USA.

Background/objectives: There is currently no consensus regarding the optimal strategy for reversal of anticoagulation in life-threatening hemorrhage associated with factor XIa (FXIa) inhibitors.

Methods: For this clinical case report, informed consent was obtained from surrogate.

Results And Discussion: Here, we present the case of an 82-year-old female who sustained a large subdural hematoma after a fall.

View Article and Find Full Text PDF

Objectives:  Antifibrinolytics, such as tranexamic acid (TXA), are widely used in cardiac surgery to reduce bleeding risks; however, the optimal dosage for TXA infusion remains a subject of debate. Hence, this study aims to evaluate the safety and efficacy of high-dose compared with low-dose TXA infusion in cardiac surgery patients.

Methods:  PubMed, SCOPUS, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched until June 10, 2023, for studies assessing efficacy outcomes (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!